EP15.06 TESTING COMMERCIALLY AVAILABLE TOPICAL SKIN CARE PRODUCTS FOR THEIR EFFECT ON TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARRAY ADHESIVENESS AND ELECTRIC CURRENTS DELIVERY

Abstract BACKGROUND Tumor Treating Fields (TTFields) therapy is an approved treatment for glioblastoma (for newly diagnosed and recurrent), pleural mesothelioma, and metastatic non-small cell lung carcinoma. TTFields therapy is delivered to patients continuously via skin-adherent arrays, creating an inherent risk of skin irritation. To maintain patient quality-of-life and increase treatment effectiveness by preserving device usage time, proactive measures should be taken for management of skin adverse events (AEs). The goal of this study was to identify which commercially available topical skin care products may be used to alleviate device-related skin irritation without compromising treatment effectiveness. MATERIAL AND METHODS We tested the effect of topical skin care products on array adhesiveness (by measuring the force needed to peel off the array) and on electric current delivery. We selected for examination products that are recommended for preserving good skin health or are customary for the treatment of skin AEs, including skin barriers, topical corticosteroids, anti-itching products, wound healing agents, topical antimicrobials, and moisturizers. We performed a wide screen in animal models on 34 compounds, and then validated the results in healthy humans for 8 of the compounds. RESULTS The preclinical tests identified 24 compounds that did not interfere with array adhesiveness or electric current delivery, coming from the various medical use groups. The products that were determined to potentially interfere with TTFields delivery contained an electrical insulator/lipid component as the major ingredient. The human study corroborated the preclinical results. CONCLUSION To properly manage skin AEs in patients treated with TTFields therapy, topical skin care products should be selected that do not compromise TTFields delivery. This study provides a selection of such commercially available products.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-10-01
DOI
https://doi.org/10.1093/neuonc/noaf193.642
Primary Topic
Microbial Inactivation Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EP15.06 TESTING COMMERCIALLY AVAILABLE TOPICAL SKIN CARE PRODUCTS FOR THEIR EFFECT ON TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARRAY ADHESIVENESS AND ELECTRIC CURRENTS DELIVERY

Itai Tzchori, A Haber, Uri Weinberg, A Klein-Goldberg et al.
Neuro-Oncology
Microbial Inactivation Methods
article

EP15.06 TESTING COMMERCIALLY AVAILABLE TOPICAL SKIN CARE PRODUCTS FOR THEIR EFFECT ON TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARRAY ADHESIVENESS AND ELECTRIC CURRENTS DELIVERY

Itai Tzchori, A Haber, Uri Weinberg, A Klein-Goldberg, Roni Blatt, Mariell Sellevoll, Gitit Lavy-Shahaf, Moshe Giladi, Yoram Palti, Sewar Zbidat, Maya Sadovnik, Stav Edelstein
article en

Abstract

Abstract BACKGROUND Tumor Treating Fields (TTFields) therapy is an approved treatment for glioblastoma (for newly diagnosed and recurrent), pleural mesothelioma, and metastatic non-small cell lung carcinoma. TTFields therapy is delivered to patients continuously via skin-adherent arrays, creating an inherent risk of skin irritation. To maintain patient quality-of-life and increase treatment effectiveness by preserving device usage time, proactive measures should be taken for management of skin adverse events (AEs). The goal of this study was to identify which commercially available topical skin care products may be used to alleviate device-related skin irritation without compromising treatment effectiveness. MATERIAL AND METHODS We tested the effect of topical skin care products on array adhesiveness (by measuring the force needed to peel off the array) and on electric current delivery. We selected for examination products that are recommended for preserving good skin health or are customary for the treatment of skin AEs, including skin barriers, topical corticosteroids, anti-itching products, wound healing agents, topical antimicrobials, and moisturizers. We performed a wide screen in animal models on 34 compounds, and then validated the results in healthy humans for 8 of the compounds. RESULTS The preclinical tests identified 24 compounds that did not interfere with array adhesiveness or electric current delivery, coming from the various medical use groups. The products that were determined to potentially interfere with TTFields delivery contained an electrical insulator/lipid component as the major ingredient. The human study corroborated the preclinical results. CONCLUSION To properly manage skin AEs in patients treated with TTFields therapy, topical skin care products should be selected that do not compromise TTFields delivery. This study provides a selection of such commercially available products.

Neuro-OncologyVol. 27(Supplement_3)
Novocure (United States) (US)
Openalex Percentile: Top 71%
Microbial Inactivation Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.